

### The effect of arachidonate lipoxigenase substrates and inhibitors on SRS-A release in the guinea-pig lung

H.R. MORRIS<sup>1</sup>, PRISCILLA J. PIPER<sup>2</sup>,  
G.W. TAYLOR<sup>1</sup> & J.R. TIPPINS<sup>2</sup>

Department of Biochemistry, Imperial College<sup>1</sup> and Department of Pharmacology, Royal College of Surgeons<sup>2</sup>, London.

The release of slow reacting substance of anaphylaxis (SRS-A) from guinea-pig lung during antigen challenge is increased by cyclo-oxygenase inhibitors (Engineer, Niederhauser, Piper & Sirois, 1978). This may be a result of inhibition by a cyclo-oxygenase product or re-direction of arachidonic acid (AA) metabolism via the lipoxigenase pathway (Hamberg, 1976; Adcock, Garland, Moncada & Salmon, 1978). Indeed, it has been suggested that SRS-A may be formed from AA by lipoxigenase (Jakschik, Falkenheim & Parker, 1977). The effects of various fatty acids, some of which are substrates for arachidonate lipoxigenase (Nugteren, 1975), on the release of SRS-A were investigated.

Lungs from guinea-pigs previously sensitised to ovalbumin were perfused free of blood and chopped into pieces (1 mm<sup>3</sup>). Aliquots (120 mg) were incubated in Tyrode solution at 37°C with or without indomethacin. In each experiment control and test aliquots were from the same lung. Fatty acids and inhibitors were added 30 min before ovalbumin challenge (50 µg/ml) to give a total volume of 3 ml. After 15 min SRS-A released into the supernatant was assayed on superfused longitudinal smooth muscle from guinea-pig ileum in the presence of mepyramine and hyoscine (5 × 10<sup>-7</sup> M). Prostaglandin release was estimated in terms of prostaglandin F<sub>2α</sub> by radioimmunoassay.

Indomethacin (1 µg/ml) increased the release of SRS-A 81% above control levels. Arachidonic acid (1–50 µg/ml) caused a dose-related increase in SRS-A output up to 162% above control; these doses of AA did not contract the guinea-pig ileum. 5, 8, 11, 14, 17 eicosapentaenoic acid, 4, 7, 10, 13, 16, 19 docosahexaenoic acid and 6, 9, 12 octadecatrienoic acid (10 µg/ml) increased SRS-A release by 100, 22 and 21% respectively. In the presence of indomethacin (1 µg/ml) the release of SRS-A by arachidonic and eicosapentaenoic acids was further increased to 199 and 128%. In all cases, SRS-A was antagonised by FPL 55712 (1 µg/ml). 11, 14 eicosadienoic, 11, 14, 17 eicosatrienoic, 9, 12, 15 octadecatrienoic and oleic acids (10 µg/ml) did not affect the release of SRS-A.

In doses of 0.3–100 µg/ml, 12 hydroxy eicosatetraenoic acid (HETE), the stable end-product of action of lipoxigenase on AA, did not potentiate the release of SRS-A. 5, 8, 11, 14 eicosatetraenoic (10 µg/ml) and nordihydroguaiaretic acid (1–50 µg/ml) (Tappel, Lundberg & Boyer, 1953) caused a dose-related inhibition of control release of SRS-A. The release of prostaglandins was unaffected by these doses of nordihydroguaiaretic acid. The indomethacin- or AA-potentiated output of SRS-A was also inhibited by nordihydroguaiaretic acid.

The fatty acids 20:4; 20:3; 20:5 and 22:6 which potentiated SRS-A release have double bonds at n-9 and n-12 (n represents position of double bonds from the terminal methyl group) and are substrates for arachidonate lipoxigenase which has an (n-9) specificity (Nugteren, 1975) whereas the inactive acids are not substrates for this enzyme. Since the output of SRS-A was decreased in the presence of lipoxigenase inhibitors these results suggest that SRS-A release is modulated by some aspect of lipoxigenase action although not affected by the stable end-product HETE.

We thank the M.R.C for a grant and Dr. P. J. Jose for preparing HETE.

### References

- ADCOCK, J.J., GARLAND, L.G., MONCADA, S. & SALMON, J.A. (1978). The mechanism of enhancement by fatty acid hydroperoxide of anaphylactic mediator release. *Prostaglandins*, **16**, 179–187.
- ENGINEER, D.M., NIEDERHAUSER, U., PIPER, P.J. & SIROIS, P. (1978). Release of mediators of anaphylaxis: inhibition of prostaglandin synthesis and the modification of release of slow reacting substance of anaphylaxis and histamine. *Br. J. Pharmacol.*, **62**, 61–66.
- HAMBERG, M. (1976). On the formation of thromboxane B<sub>2</sub> and 12L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid (12 ho-20:4) in tissues from the guinea-pig *Biochim. Biophys. Acta*, **431**, 651–654.
- JAKSHIK, B.A., FALKENHEIN, S. & PARKER, C.W. (1977). Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells. *Proc. natn. Acad. Sci. U.S.A.*, **74**, 4577–4581.
- NUGTEREN, D.H. (1975). Arachidonate lipoxigenase in blood platelets. *Biochim. Biophys. Acta*, **380**, 299–307.
- TAPPEL, A.L., LUNDBERG, W.O. & BOYER, P.D. (1953). Effect of temperature and antioxidants upon the lipoxidase-catalyzed oxidation of sodium linoleate. *Arch. Biochem. Biophys.*, **42**, 293–304.